IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio(R) in Combination with KEYTRUDA(R) (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma GlobeNewswire August 10, 2025 NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference […]

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your 3D Systems Corporation (NYSE:DDD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/3d-systems-corporation-lawsuit-submission-form?prid=160628&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Lockheed Martin Corporation (NYSE:LMT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=160627&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Sable Offshore Corp. (NYSE:SOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sable-offshore-corp-lawsuit-submission-form?prid=160629&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your RxSight, Inc. (NASDAQ:RXST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=160630&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Hims & Hers Health, Inc. (NYSE:HIMS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/hims-hers-health-inc-lawsuit-submission-form?prid=160631&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Flywire Corporation (NASDAQ:FLYW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/flywire-corporation-lawsuit-submission-form?prid=160632&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Fiserv, Inc. (NYSE:FI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?prid=160634&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Alto Neuroscience, Inc. (NYSE:ANRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=160633&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=160635&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or